Literature DB >> 29191689

Does the surgical waiting list affect pathological and survival outcome in resectable pancreatic ductal adenocarcinoma?

Giovanni Marchegiani1, Stefano Andrianello1, Giampaolo Perri1, Erica Secchettin1, Laura Maggino1, Giuseppe Malleo1, Claudio Bassi2, Roberto Salvia1.   

Abstract

BACKGROUND: High-volume centers have to deal with long surgical waiting-lists leading to a potential delay in treatment. This study assessed whether a longer time from diagnosis to surgery worsened pathological and survival outcomes in resectable pancreatic ductal adenocarcinoma (PDAC).
METHODS: A retrospective analysis of patients treated for resectable PDAC. Difference in size between preoperative CT-scan and specimen, pathological features, the rate of vascular and R1 resections as well as recurrence and survival were analyzed depending on the waiting time using a 30-day cut-off.
RESULTS: Waiting more than 30 days for surgery was associated with an increase in tumor size on specimen when compared with CT-scan (+3 vs. +1 mm, p = 0.04). T and N status, rate of vascular resection, grading, perineural and lymphovascular infiltration, and R1 rates did not differ between groups, as well as tumor recurrence (48.8% vs. 48.9%, p = 0.5) and survival (31 vs. 29 months, p = 0.7). For PDAC < 20 mm, waiting less than 30 days improved overall survival (p = 0.02).
CONCLUSION: The duration of the surgical waiting-list did not affect pathological features and survival. Delayed surgery was associated with increased cancer size on the specimen. However, surgery should not be delayed for PDACs < 20 mm as this may negatively affect the prognosis.
Copyright © 2017 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29191689     DOI: 10.1016/j.hpb.2017.10.017

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  11 in total

Review 1.  Pancreatoduodenectomy associated with colonic resections: indications, pitfalls, and outcomes.

Authors:  Tommaso Giuliani; Anthony Di Gioia; Stefano Andrianello; Giovanni Marchegiani; Claudio Bassi
Journal:  Updates Surg       Date:  2021-02-13

Review 2.  Surgical safety in the COVID-19 era: present and future considerations.

Authors:  Young Il Kim; In Ja Park
Journal:  Ann Surg Treat Res       Date:  2022-06-07       Impact factor: 1.766

3.  Deeper insights into long-term survival heterogeneity of pancreatic ductal adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses.

Authors:  Archana Bhardwaj; Claire Josse; Daniel Van Daele; Christophe Poulet; Marcela Chavez; Ingrid Struman; Kristel Van Steen
Journal:  Sci Rep       Date:  2022-06-30       Impact factor: 4.996

4.  Gastrointestinal Malignancies and the COVID-19 Pandemic: Evidence-Based Triage to Surgery.

Authors:  Scott C Fligor; Sophie Wang; Benjamin G Allar; Savas T Tsikis; Ana Sofia Ore; Ashlyn E Whitlock; Rodrigo Calvillo-Ortiz; Kevin R Arndt; Sidhu P Gangadharan; Mark P Callery
Journal:  J Gastrointest Surg       Date:  2020-06-30       Impact factor: 3.452

5.  The survival impact of surgical waiting time in patients with resectable pancreatic head cancer.

Authors:  Hye Kyoung Seo; Dae Wook Hwang; Seo Young Park; Yejong Park; Seung Jae Lee; Jae Hoon Lee; Ki Byung Song; Young-Joo Lee; Song Cheol Kim
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2018-11-27

6.  Evaluation of the clinical and economic impact of delays to surgery in patients with periampullary cancer.

Authors:  R Pandé; J Hodson; A Murray; F Marcon; M Kalisvaart; R Marudanayagam; R P Sutcliffe; D F Mirza; J Isaac; K J Roberts
Journal:  BJS Open       Date:  2019-04-02

7.  Impact of time interval between multidisciplinary team meeting and intended pancreatoduodenectomy on oncological outcomes.

Authors:  M W Steen; L B van Rijssen; S Festen; O R Busch; B Groot Koerkamp; L G van der Geest; I H de Hingh; H C van Santvoort; M G Besselink; M F Gerhards
Journal:  BJS Open       Date:  2020-08-25

Review 8.  Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine.

Authors:  R Casolino; C Braconi; G Malleo; S Paiella; C Bassi; M Milella; S B Dreyer; F E M Froeling; D K Chang; A V Biankin; T Golan
Journal:  Ann Oncol       Date:  2020-11-26       Impact factor: 32.976

9.  Time from first seen in specialist care to surgery does not influence survival outcome in patients with upfront resected pancreatic adenocarcinoma.

Authors:  M Brugel; O Bouché; R Kianmanesh; L Teuma; A Tashkandi; J M Regimbeau; P Pessaux; B Royer; R Rhaiem; C Perrenot; C Neuzillet; T Piardi; S Deguelte
Journal:  BMC Surg       Date:  2021-12-07       Impact factor: 2.102

10.  What is Elective Oncologic Surgery in the Time of COVID-19? A Literature Review of the Impact of Surgical Delays on Outcomes in Patients with Cancer.

Authors:  Denise Garcia; Julie B Siegel; David A Mahvi; Biqi Zhang; David M Mahvi; E Ramsay Camp; Whitney Graybill; Stephen J Savage; Antonio Giordano; Sara Giordano; Denise Carneiro-Pla; Mahsa Javid; Aaron P Lesher; Andrea Abbott; Nancy Klauber DeMore
Journal:  Clin Oncol Res       Date:  2020-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.